Heartland HY24: PBT down 23.8% and interim dividend cut 27%

What changed

Net operating income eased 2.0% to $141.2m, but earnings fell disproportionately: PBT dropped 23.8% to $52.6m and reported NPAT fell 22.7% to $37.6m. Management's underlying NPAT of $52.7m implies roughly $15m of below-the-line adjustments, with the release pointing to fair value movements on investments and an impaired asset expense as the drivers of the gap between operating profit ($74.7m) and PBT ($52.6m).

The balance sheet expanded meaningfully. Gross borrowings rose 8.0% to $6.83bn and total assets grew 6.6% to $7.93bn, while equity was essentially flat at $1.02bn. Cash fell to $286.9m from $385.3m. The interim dividend was cut to 4.0cps from 5.5cps, a 27.3% reduction.

Reported operating cash flow swung to an $8.8m outflow from a $262.2m inflow in HY23 — a movement dominated by lending book dynamics rather than core profitability, but still a sharp change in direction.

What matters

• The gap between reported and underlying NPAT. Reported NPAT is ~29% below management's preferred underlying measure. The excerpts flag fair value gains on investments and impaired asset expense as the adjustment items, but a full bridge is not reproduced. That is the most consequential read on earnings quality this half.
• Leverage is weakening while ROE compresses. Inferred net debt rose to about $6.55bn from $5.94bn, equity barely moved, and ROE fell to 7.4% from 9.6%. Balance-sheet growth is not translating into earnings power at HY23 rates.
• The dividend cut. A 27.3% reduction in the interim DPS is a clear capital-allocation signal. The payout ratio against reported NPAT is effectively unchanged at ~75.5%, so the cut tracks the earnings decline rather than a conscious payout rebase.

Expectations

No quantitative guidance or forward-work target was disclosed. Against FY23 shape, HY23 was 49.7% of FY23 revenue and 50.8% of FY23 NPAT, so the business is not structurally second-half weighted. Annualising HY24 revenue gives ~$282.5m, below the FY23 anchor of $289.8m, implying the run-rate has softened modestly rather than accelerated. Reaching FY23 NPAT of $95.9m from an HY24 base of $37.6m would require a materially stronger second half than HY24, which the release does not underwrite with any stated target.

Quality of result

Mixed-to-weak. The 2% revenue decline is mild, but PBT fell 23.8% with no tax-rate distortion (effective tax rate 28.5% vs 29.5%), so the deterioration is genuinely operating and below-operating-profit items, not a tax artefact. The $15m reconciling item between reported and underlying NPAT is material enough that reported earnings quality hinges on whether the fair value and impairment charges are truly one-off.

Cash conversion materially deteriorated at the headline level, but for a lending group the $271m OCF swing reflects growth in the receivables book funded by deposits and other borrowings rather than a working-capital shock in the operating sense. Capex more than doubled to $16.7m (11.8% of revenue vs 5.4%), which is a real cash call on top of the receivables growth. Pre-lease free cash flow of -$25.5m does not cover the declared interim dividend on a period basis.

Unresolved

• What specifically drove the $15m gap between reported NPAT ($37.6m) and underlying NPAT ($52.7m), and how much of the fair value loss and impaired asset expense is genuinely non-recurring?
• What is the asset-quality trend behind the impaired asset expense, and is it concentrated in one segment (Motor Finance is the largest NOI contributor at 22%)?
• Why did capex roughly double to $16.7m, and is this a step-up or a one-off?
• Is the 4.0cps interim the new baseline, or expected to be topped up at the final?
• What NIM and cost-to-income trajectory underpins the operating profit decline from $80.7m to $74.7m?

This briefing cannot assess forward earnings trajectory, credit-quality detail, or valuation, because no guidance, arrears disclosure, or NTA per share was provided in the extracted data.

Key metrics

Segment breakdown

Analytical metrics

---

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.